SEC Form 4 · accession 0001232524-17-000158
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director
Period of report
Aug 25, 2017
Accepted (ET)
Aug 28, 2017 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 25, 2017 | S | 351 | $148.40 | D | 1,717 | D | |
| Ordinary SharesF2 | holding | — | — | — | 4,323 | I | By Longitude Capital | |
| Ordinary SharesF2 | holding | — | — | — | 215,677 | I | By Longitude Venture |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2The Reporting Person is a managing member of Longitude Capital Partners, LLC, the general partner each of Longitude Venture Partners, L.P. ("Longitude Venture") and Longitude Capital Associates, L.P. ("Longitude Capital"). The Reporting Person disclaims beneficial ownership of the securities of the Issuer held by Longitude Venture and Longitude Capital, except to the extent of his pecuniary interest therein.